CA3209732A1 - Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof - Google Patents
Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof Download PDFInfo
- Publication number
- CA3209732A1 CA3209732A1 CA3209732A CA3209732A CA3209732A1 CA 3209732 A1 CA3209732 A1 CA 3209732A1 CA 3209732 A CA3209732 A CA 3209732A CA 3209732 A CA3209732 A CA 3209732A CA 3209732 A1 CA3209732 A1 CA 3209732A1
- Authority
- CA
- Canada
- Prior art keywords
- polynucleotide sequence
- seq
- sequence
- amino acid
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/90—Vectors containing a transposable element
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Polyethers (AREA)
- Fuel Cell (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163153862P | 2021-02-25 | 2021-02-25 | |
| US63/153,862 | 2021-02-25 | ||
| US202163159434P | 2021-03-10 | 2021-03-10 | |
| US63/159,434 | 2021-03-10 | ||
| US202163260409P | 2021-08-19 | 2021-08-19 | |
| US63/260,409 | 2021-08-19 | ||
| US202163260855P | 2021-09-02 | 2021-09-02 | |
| US63/260,855 | 2021-09-02 | ||
| US202263267421P | 2022-02-01 | 2022-02-01 | |
| US63/267,421 | 2022-02-01 | ||
| PCT/US2022/070690 WO2022183167A1 (en) | 2021-02-25 | 2022-02-17 | Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3209732A1 true CA3209732A1 (en) | 2022-09-01 |
Family
ID=80628943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3209732A Pending CA3209732A1 (en) | 2021-02-25 | 2022-02-17 | Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240175047A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4298121A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2024507929A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20230150336A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2022227085A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3209732A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL305393A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2022183167A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230159614A1 (en) * | 2020-02-26 | 2023-05-25 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Hla class ii-restricted t cell receptors against ras with g12v mutation |
| WO2023150562A1 (en) * | 2022-02-01 | 2023-08-10 | Alaunos Therapeutics, Inc. | Methods for activation and expansion of t cells |
| WO2023183344A1 (en) | 2022-03-21 | 2023-09-28 | Alaunos Therapeutics, Inc. | Methods for identifying neoantigen-reactive t cell receptors |
| JP2025530339A (ja) * | 2022-09-13 | 2025-09-11 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 変異型rasを標的化するためのt細胞受容体及びその組成物 |
| WO2024163371A1 (en) * | 2023-01-30 | 2024-08-08 | Fred Hutchinson Cancer Center | Binding proteins specific for mutant p53 and uses thereof |
| WO2024197072A2 (en) | 2023-03-21 | 2024-09-26 | Alaunos Therapeutics, Inc. | Identification of neoantigen-reactive t cell receptors |
| AU2024241888A1 (en) * | 2023-03-27 | 2025-10-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors targeting y220c or r175h mutation in p53 |
| CN117143823B (zh) * | 2023-09-11 | 2024-07-16 | 皖南医学院第一附属医院(皖南医学院弋矶山医院) | 一种基于tcr单链可变区的靶向ras(g12v)的嵌合抗原受体记忆nk细胞的研制及其应用 |
| WO2025056681A1 (en) * | 2023-09-15 | 2025-03-20 | Medigene Immunotherapies Gmbh | T-CELL RECEPTOR AGAINST mKRAS7-16 G12V AND G12C |
| WO2025096983A1 (en) * | 2023-11-02 | 2025-05-08 | Board Of Regents, The University Of Texas System | Peptides and engineered t cell receptors targeting tpx2 antigen and methods of use |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996018105A1 (en) | 1994-12-06 | 1996-06-13 | The President And Fellows Of Harvard College | Single chain t-cell receptor |
| DK0973928T3 (da) | 1997-03-11 | 2010-08-09 | Univ Minnesota | DNA-baseret transposonsystem til indføring af nukleinsyre i DNA i en celle |
| GB9809658D0 (en) | 1998-05-06 | 1998-07-01 | Celltech Therapeutics Ltd | Biological products |
| IL127142A0 (en) | 1998-11-19 | 1999-09-22 | Yeda Res & Dev | Immune cells having predefined biological specificity |
| JP2002541845A (ja) | 1999-04-16 | 2002-12-10 | セルテック セラピューティックス リミテッド | 合成膜貫通成分 |
| PT1421115E (pt) | 2001-08-31 | 2005-07-29 | Avidex Ltd | Receptor de celulas t soluvel |
| US20040014194A1 (en) | 2002-03-27 | 2004-01-22 | Schering Corporation | Beta-secretase crystals and methods for preparing and using the same |
| WO2003089618A2 (en) | 2002-04-22 | 2003-10-30 | Regents Of The University Of Minnesota | Transposon system and methods of use |
| AU2003271904B2 (en) | 2002-10-09 | 2009-03-05 | Adaptimmune Limited | Single chain recombinant T cell receptors |
| EP1791865B1 (en) | 2004-06-29 | 2010-07-28 | Immunocore Ltd. | Cells expressing a modified t cell receptor |
| GB0712670D0 (en) | 2007-06-29 | 2007-08-08 | King S College London | Isolated peptides and uses thereof |
| US9228180B2 (en) | 2007-07-04 | 2016-01-05 | Max-Delbruck-Centrum Fur Molekulare Medizin | Polypeptide variants of sleeping beauty transposase |
| WO2011044186A1 (en) | 2009-10-06 | 2011-04-14 | The Board Of Trustees Of The University Of Illinois | Human single-chain t cell receptors |
| CA3285826A1 (en) | 2012-02-22 | 2026-03-02 | The Trustees Of The University Of Pennsylvania | Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer |
| PT2692865E (pt) | 2012-07-30 | 2015-02-06 | Nbe Therapeutics Llc | Identificação mediada por transposição de proteínas funcionais ou de ligação específicas |
| SG10201913978RA (en) | 2014-11-26 | 2020-03-30 | The United States Of America As Represented By The Secretary | Anti-mutated kras t cell receptors |
| JP6775515B2 (ja) | 2015-03-11 | 2020-10-28 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | トランスポザーゼポリペプチド及びその使用 |
| SG10201913868XA (en) | 2015-09-15 | 2020-03-30 | The United States Of America As Represented By The Secretary | T cell receptors recognizing hla-cw8 restricted mutated kras |
| SG11201900654QA (en) | 2016-08-02 | 2019-02-27 | Us Health | Anti-kras-g12d t cell receptors |
| WO2018209115A1 (en) | 2017-05-10 | 2018-11-15 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof |
| EP3635132A4 (en) * | 2017-06-07 | 2021-05-26 | Intrexon Corporation | EXPRESSION OF NOVEL CELL MARKERS |
| AU2018321105B2 (en) | 2017-08-21 | 2025-01-30 | European Molecular Biology Laboratory | Improved transposase polypeptide and uses thereof |
| AU2018335274B2 (en) | 2017-09-20 | 2025-02-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | HLA class II–restricted T cell receptors against mutated RAS |
| IL273515B2 (en) | 2017-09-29 | 2026-03-01 | Us Health | T cell receptors that recognize mutated P53 |
| JP7391015B2 (ja) | 2017-09-29 | 2023-12-04 | アメリカ合衆国 | P53がん特異的変異に対して抗原特異性を有するt細胞を単離する方法 |
| US12227554B2 (en) | 2017-10-05 | 2025-02-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods for selectively expanding cells expressing a TCR with a murine constant region |
| MX2020005765A (es) | 2017-12-04 | 2020-09-25 | Us Health | Receptores de celulas t restringidos a antigeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado. |
| WO2019160956A1 (en) * | 2018-02-13 | 2019-08-22 | Novartis Ag | Chimeric antigen receptor therapy in combination with il-15r and il15 |
| EP3561053A1 (en) * | 2018-04-26 | 2019-10-30 | Baylor College of Medicine | Immune effector cells and molecular adaptors with an antigen cytokine complex for effective cancer immunotherapy |
| AU2019263233B2 (en) | 2018-05-01 | 2024-08-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors which recognize mutated EGFR |
| US20200129555A1 (en) | 2018-10-24 | 2020-04-30 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Hla-a3-restricted t cell receptors against mutated ras |
| US20220033848A1 (en) * | 2018-11-19 | 2022-02-03 | Board Of Regents, The University Of Texas System | A modular, polycistronic vector for car and tcr transduction |
| WO2020154275A1 (en) | 2019-01-22 | 2020-07-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hla class ii-restricted t cell receptors against ras with g12r mutation |
| WO2020264269A1 (en) | 2019-06-27 | 2020-12-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors recognizing r175h or y220c mutation in p53 |
| CA3168015A1 (en) | 2020-02-12 | 2021-08-19 | Noam LEVIN | Hla class i-restricted t cell receptors against ras with g12d mutation |
| MX2022009825A (es) | 2020-02-14 | 2022-10-13 | Us Health | Receptores de células t restringidas por hla de la clase i contra ras con mutación g12v. |
| US20230159614A1 (en) | 2020-02-26 | 2023-05-25 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Hla class ii-restricted t cell receptors against ras with g12v mutation |
-
2022
- 2022-02-17 JP JP2023551669A patent/JP2024507929A/ja active Pending
- 2022-02-17 WO PCT/US2022/070690 patent/WO2022183167A1/en not_active Ceased
- 2022-02-17 CA CA3209732A patent/CA3209732A1/en active Pending
- 2022-02-17 IL IL305393A patent/IL305393A/en unknown
- 2022-02-17 EP EP22708022.3A patent/EP4298121A1/en not_active Withdrawn
- 2022-02-17 KR KR1020237032793A patent/KR20230150336A/ko active Pending
- 2022-02-17 AU AU2022227085A patent/AU2022227085A1/en not_active Abandoned
- 2022-02-17 US US18/547,827 patent/US20240175047A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022183167A1 (en) | 2022-09-01 |
| JP2024507929A (ja) | 2024-02-21 |
| KR20230150336A (ko) | 2023-10-30 |
| US20240175047A1 (en) | 2024-05-30 |
| EP4298121A1 (en) | 2024-01-03 |
| IL305393A (en) | 2023-10-01 |
| AU2022227085A1 (en) | 2023-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240175047A1 (en) | Recombinant Vectors Comprising Polycistronic Expression Cassettes and Methods of Use Thereof | |
| JP7317793B2 (ja) | 改変γδT細胞 | |
| EP3481867B1 (en) | Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof | |
| US12060394B2 (en) | Nucleic acid constructs for co-expression of chimeric antigen receptor and transcription factor, cells containing and therapeutic use thereof | |
| JP7627080B2 (ja) | B7h3キメラ抗原受容体を含む方法および組成物 | |
| US20210147800A1 (en) | Methods for producing regulatory immune cells and uses thereof | |
| JP2019536437A (ja) | Hpv特異的結合分子 | |
| CA3053592A1 (en) | Antibody targeting il-13ra2 and use thereof | |
| KR20230010228A (ko) | 자연 살해 세포를 표적으로 하는 키메라 항원 수용체 (cars) | |
| TW202432581A (zh) | 改善免疫細胞功能 | |
| US20250145950A1 (en) | Methods for Activation and Expansion of T Cells | |
| WO2022206994A1 (en) | Engineered immune cells and uses thereof | |
| WO2021232050A1 (en) | Natural killer cell immunotherapy for the treatment or prevention of sars-cov-2 infection | |
| US20240316201A1 (en) | Engineered immune effector cells expressing exogenously introduced cytokines | |
| EP4583905A1 (en) | Novel dual split car-t cells for the treatment of cd38-positive hematological malignancies | |
| US20230279350A1 (en) | Dual car-t cells | |
| CN117098772A (zh) | 包含多顺反子表达盒的重组载体及其使用方法 | |
| HK40101165A (en) | Engineered immune cells and uses thereof | |
| WO2026085184A1 (en) | Cd2 chimeric switch receptors and uses thereof for adoptive cell transfer immunotherapy | |
| CN121896173A (zh) | 表达外源肌苷单磷酸脱氢酶的真核细胞 | |
| HK40008962B (en) | Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof | |
| HK40008962A (en) | Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R113 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS OR METHOD OF CORRESPONDENCE REQUEST RECEIVED Effective date: 20241120 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241220 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241220 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241220 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251210 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251210 |
|
| R18 | Changes to party contact information recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R18-R143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260407 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260407 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260526 |